Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06517888 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. 3 versions Re-verified since Mar 3, 2026, no change to tracked fieldsv12-v14
  2. Site contacts updated at 1 of 4 sitesv11
  3. Re-verified, no change to tracked fieldsv10
  4. Site contacts updated at 1 of 4 sitesv9
  5. Study sites: 3 to 4v8
Show 6 earlier versionsHide 6 earlier versions
  1. Study sites: 2 to 3v7
  2. Start date changed from estimate of Sep 2024 to Jan 17, 2025
    • Site contacts updated at 2 of 2 sites
    v6
  3. Study sites: 1 to 2v5
  4. Eligibility criteria shortened, about 2 wordsv4
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v3
  6. Lead sponsor: [Redacted] to Akouos, Inc.v2 Show 5 more changesShow less
    • Trial status: Withheld to Not Yet Recruiting
    • Primary and study completion dates: Aug 2029
    • Start date: Sep 2024
    • Study title shortened, about 6 words
    • Collaborators expanded, about 4 words
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial will evaluate the safety and tolerability of a single unilateral administration of one of three dose levels of AAVAnc80-antiVEGF and will evaluate the Akouos delivery device to safely achieve the intended product performance.
Trial Details
NCT Number NCT06517888
Lead Sponsor Akouos, Inc.
Collaborators: Eli Lilly and Company
Conditions
(from sponsor)		 Vestibular Schwannoma
Related terms Hearing Loss, Neuroma, Acoustic
Enrollment 27 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov